Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 566 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vaginal Diseases Clear all

Conditions: Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Vaginal Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Therapy-related Toxicity
Interventions: triapine, cisplatin, external beam radiation therapy, quality-of-life assessment, questionnaire administration, fludeoxyglucose F 18, positron emission tomography, computed tomography; Drug · Radiation · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obstetric; Injury Pelvic Floor, Sexual Dysfunction, Anal Incontinence, Urinary Incontinence
Interventions: Estradiol 0.01% Vag Cream, Placebo vaginal cream; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Uterine Prolapse
Interventions: Laparoscopic supracervical hysterectomy with sacropexy, Vaginal hysterectomy with uterosacral colposuspension; Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Premature Birth
Interventions: Vaginal Progesterone gel., fetal fibronectin swab., Placebo gel; Drug · Procedure
Lead sponsor: Obstetrix Medical Group; Industry
Eligibility: 18 Years to 60 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Jose, California

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Oteseconazole (VT-1161), Placebo; Drug
Lead sponsor: Mycovia Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Vulvovaginal Candidiasis
Interventions: SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test); Device
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Fort Bragg, North Carolina • Fort Sam Houston, Texas

Conditions: Pelvic Organ Prolapse (POP)
Interventions: Restorelle Direct Fix A&P; Device
Lead sponsor: Coloplast A/S; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Baltimore, Maryland • Grand Rapids, Michigan • Marshall, Missouri + 3 more

Conditions: Bacterial Vaginosis
Interventions: Flourish HEC Vaginal Care System; Device
Lead sponsor: Vaginal Biome Science; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: HIV Infections
Interventions: PRO 2000; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Pelvic Organ Prolapse, Vaginal Atrophy
Interventions: Vaginal conjugated estrogen cream 0.5gm, Vaginal conjugated estrogen cream 1.0gm; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 45 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Endometriosis, Microbiome Dysbiosis, Gastrointestinal Symptoms
Interventions: Fiber, Placebo; Dietary Supplement
Lead sponsor: LOAM Science; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer, Hot Flashes, Menopausal Symptoms
Interventions: conjugated estrogens, medroxyprogesterone; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 24
States / cities: Birmingham, Alabama • Chicago, Illinois • Decatur, Illinois + 16 more

Conditions: Bacterial Vaginosis
Interventions: tinidazole, metronidazole; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cervical Cancer
Interventions: Velcade (bortezomib), Irinotecan; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Atrophic Vaginitis, Breast Cancer
Interventions: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: HIV Infections
Interventions: UC-781, UC-781 placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Preterm Delivery, Short Cervix, Short Uterine Cervical Length
Interventions: progesterone, placebo; Drug
Lead sponsor: Juniper Pharmaceuticals, Inc.; Industry
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 465 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 27
States / cities: Mobile, Alabama • Phoenix, Arizona • Orange, California + 21 more

Conditions: Vulvar Cancer, Ovarian Cancer, Uterine Cancer, Vaginal Cancer
Interventions: Intervention group triads; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Pelvic Organ Prolapse
Interventions: Restorelle Direct Fix A, Restorelle Direct Fix P, Native Tissue Repair Anterior, Native Tissue Repair Posterior; Device · Procedure
Lead sponsor: Coloplast A/S; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 33
States / cities: Agoura Hills, California • Stanford, California • Denver, Colorado + 30 more

Conditions: Post-menopause, Pre-menopause, Sexual Function, Menopause, Vaginal Dryness, Painful Intercourse
Interventions: DHEA ovals, Estradiol 0.01% Vag Cream; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 40 Years to 90 Years · Female only
Enrollment: 324 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Multiple Sclerosis, Neurogenic Bladder
Interventions: vaginal estriol; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Papanicolaou Smear
Interventions: no-stirrup vaginal examination, Vaginal speculum examination done with stirrups.; Procedure
Lead sponsor: Eisenhower Army Medical Center; Federal
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Fort Gordon, Georgia

Conditions: Bacterial Vaginosis
Interventions: Product 55394, Placebo Vehicle (non-treatment); Drug
Lead sponsor: Medicis Global Service Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Mesa, California + 34 more

Conditions: Leiomyoma, Laparoscopy, Uterine Myomectomy
Interventions: Standard, Standard-vaginal misoprostol; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Brooklyn, New York

Search by objective public record fields.

Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery

Comparison of Laparoscopic to Vaginal Surgical Repair for Uterine Prolapse

Vaginal Progesterone in Twins With Short Cervix

A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Comparative Performance of a Vaginal Yeast Test

Restorelle Direct Fix Anterior and Posterior (A&P) for Female Pelvic Organ Prolapse: A Prospective Post Market Study

Effect of Flourish HEC Vaginal Care System on BV Recurrence and the Vaginal Microbiome

Safety and Tolerability of the Vaginal Gel PRO 2000/5

The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse

Trial Evaluating Nutritional Fiber in Digestive Symptoms of Endometriosis

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer

Treatment of Bacterial Vaginosis (BV) With Tinidazole

Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer

Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen

Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide

PREGNANT Short Cervix Trial

Study of a Rapid Triadic Communication Intention Elicitation Intervention to Improve Supportive Oncology Care Delivery

Restorelle® Mesh Versus Native Tissue Repair for Prolapse

VEDA Study (DHEA vs Estradiol)

Vaginal Estriol in Multiple Sclerosis

Eisenhower's Alternative Speculum Examination

Safety and Efficacy Study to Treat Bacterial Vaginosis

Combined Vaginal Misoprostol and Perivascular Vasopressin